Skip to content
AIPressRoom

FundingHealthcare & Biotech

ODAIA Raises $15M to Expand Pharma AI Platform

ODAIA raised $15M Series C led by Monograph Capital to expand its AI-powered commercial intelligence platform for pharmaceutical companies.

ODAIA raises $15M

The big picture: ODAIA, a Toronto-based artificial intelligence company specializing in predictive commercial intelligence for the pharmaceutical industry, raised $15 million in Series C financing to expand its enterprise customer relationships and accelerate development of its AI-powered commercial intelligence platform.

Why it matters:

  • Scaling AI: Pharmaceutical companies have proven AI’s value in commercial operations but often face additional implementation costs when extending capabilities across multiple products and therapeutic areas.
  • Integrated Intelligence: ODAIA’s centralized platform aims to address this by supporting multiple brands with shared data infrastructure and configurable decision-making tools, integrating AI into sales, marketing, and commercial decision-making.
  • Strategic Partnership: The financing includes a strategic investment from PHM, a U.S. healthcare media agency owned by Publicis Groupe, which will connect ODAIA’s predictive intelligence with PHM’s media capabilities to coordinate digital marketing and field sales engagement.

How it works:

  • Predictive Analytics: ODAIA’s platform uses machine learning to analyze healthcare professional data, patient-related signals, prescription trends, field sales activities, and digital engagement information.
  • Targeted Engagement: It generates recommendations for pharmaceutical commercial teams, helping identify prescribing opportunities, prioritize healthcare professional engagement, and coordinate activities across therapeutic areas.
  • Explainable AI: The platform incorporates explainable AI capabilities, allowing commercial and compliance teams to review the reasoning behind its recommendations, with continuous measurement of engagement and prescription outcomes to refine future advice.

The catch: The pharmaceutical AI market is becoming increasingly competitive, with numerous players offering specialized solutions for various commercial functions. ODAIA’s challenge will be to differentiate its centralized platform effectively and demonstrate superior return on investment compared to point solutions or in-house development efforts, especially as large pharmaceutical companies may prefer custom-built systems.

Key Facts

  • Company: ODAIA
  • Amount: $15M
  • Round: Series C
  • Investors: Monograph Capital (lead), PHM, BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures, Wittington Ventures
  • Founder: Philip Poulidis
  • Sector: Predictive Commercial Intelligence for Pharma
  • Headquarters: Toronto, Canada

AIPressRoom Weekly

Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.

More in Healthcare & Biotech

All